Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus

Nomura, Shosaku; Shouzu, Akira; Omoto, Seitaro; Inami, Norihito; Tanaka, Atsushi; Nanba, Masashi; Shouda, Yoshihiro; Takahashi, Nobuyuki; Kimura, Yutaka; Iwasaka, Toshiji

doi:10.1016/j.thromres.2007.08.013

Cited by 47 publications

(46 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hypoadiponectinemia also seems to cause platelet activation. The level of NO, which regulates platelet activation, is decreased by hypoadiponectinemia because adiponectin stimulates NO production by vascular endothelial cells [34][35][36]. Thus, platelet activation occurs due to low NO concentrations in persons with hypoadiponectenemia.…”

Section: Discussionmentioning

confidence: 99%

Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients

Shimazu

Inami

Satoh

et al. 2009

J Thromb Thrombolysis

Self Cite

View full text Add to dashboard Cite

Platelet-derived microparticles (PDMP), selectins, and adiponectin play an important role in the development of atherosclerosis in diabetes. Acarbose has been shown to have a beneficial effect on postprandial hyperglycemia in diabetic patients. However, its influence on PDMP, selectins, and adiponectin in these patients is poorly understood. We investigated the effect of acarbose on circulating levels of PDMP, selectins, and adiponectin in patients with type 2 diabetes. Acarbose (300 mg/day) was administered for 3 months. Levels of PDMP, sP-selectin, sL-selectin, and adiponectin were measured by ELISA at baseline and after 1 and 3 months of treatment. The levels of PDMP, sP-selectin, and sL-selectin were higher in diabetic patients than in hypertensive patients (PDMP; 35.1 +/- 34.2 vs. 53.3 +/- 56.7 U/ml, P < 0.05: sP-selectin; 134 +/- 52 vs. 235 +/- 70 ng/dl, P < 0.01: sL-selectin; 569 +/- 183 vs. 805 +/- 146 ng/ml, P < 0.05), while there were no significant differences between hypertensive and hyperlipidemic patients. Before acarbose treatment, the adiponectin level of diabetic patients was lower than that of hypertensive patients. Acarbose therapy significantly decreased the plasma PDMP level relative to baseline. Acarbose also caused a significant decrease of sP-selectin and sL-selectin. On the other hand, acarbose therapy led to a significant increase of adiponectin after 3 months of administration compared with baseline (adiponectin: diabetes versus hypertension, 3.61 +/- 1.23 vs. 5.87 +/- 1.92 microg/ml, P < 0.05; diabetes versus controls, 2.81 +/- 0.95 vs. 6.13 +/- 1.24 microg/ml, P < 0.01). Twelve of the 30 diabetic patients had a history of thrombotic complications. Furthermore, the reduction of PDMP and selectins during acarbose therapy was significantly greater in the thrombotic group (12 of 30) than in the nonthrombotic group (18 of 30) of diabetic patients. Acarbose may be beneficial for primary prevention of atherothrombosis in patients with type 2 diabetes. However, it requires a large clinical trial to test this hypothesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients

Shimazu

Inami

Satoh

et al. 2009

J Thromb Thrombolysis

Self Cite

View full text Add to dashboard Cite

show abstract

“…80 Several clinical studies have also found that pitavastatin possesses an adiponectin-increasing effect in hyperlipidemic patients with and without T2D. [85][86][87][88][89][90] Adiponectin is a protein with antiatherosclerotic, anti-inflammatory, and antidiabetogenic properties exerted on liver, skeletal muscle, adipose tissue and pancreatic β-cells. 90 Mechanistically, adiponectin stimulates AMPK, a kinase that suppresses energy-consuming pathways such as hexosamine and cholesterol biosynthesis.…”

Section: Review Diabetesmentioning

confidence: 99%

New Aspects of Cellular Cholesterol Regulation on Blood Glucose Control—Review and Perspective on the Impact of Statin Medications on Metabolic Health

Grice

Elmendorf

2017

US Endocrinology

View full text Add to dashboard Cite

Cholesterol is an essential component of cell membranes, and during the past several years, diabetes researchers have found that membrane cholesterol levels in adipocytes, skeletal muscle fibers and pancreatic beta cells influence insulin action and insulin secretion. Consequently, it is thought that dysregulated cell cholesterol homeostasis could represent a determinant of type 2 diabetes (T2D). Recent clinical findings compellingly add to this notion by finding increased T2D susceptibility in individuals with alterations in a variety of cholesterol metabolism genes. While it remains imperfectly understood how statins influence glucose metabolism, the fact that they display an influence on blood glucose levels and diabetes susceptibility seems to intensify the emerging importance of understanding cellular cholesterol in glucose metabolism. Taking this into account, this review first presents cell system and animal model findings that demonstrate the negative impact of cellular cholesterol accumulation or diminution on insulin action and insulin secretion. With this framework, a description of how changes in cholesterol metabolism genes are associated with T2D susceptibility will be presented. In addition, the connection between statins and T2D risk will be reviewed with expanded information on pitavastatin, a newer statin medication that displays actions favoring metabolic health.

show abstract

“…Atorvastatin 10 mg/day for 24 weeks Plasma sCD40L levels increased by 5.9% (p = 0.68) Nomura et al 60 Hyperlipidemic T2DM subjects (n = 45) …”

Section: Key Messagesmentioning

confidence: 99%

CD40–CD40L: Linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications

Seijkens

Kusters

Engel

et al. 2012

Diabetes and Vascular Disease Research

View full text Add to dashboard Cite

Numerous epidemiological studies have consistently demonstrated the strong association between type 2 diabetes mellitus (T2DM) and an increased risk to develop cardiovascular disease. The pathogenesis of T2DM and its complications are characterized by pancreatic, adipose tissue and vascular inflammation. CD40 and CD40L, members of the tumour necrosis factor (receptor) TNF(R) family, are well known for their role in immunity and inflammation. Here we give an overview on the role of CD40-CD40L interactions in the pathogenesis of T2DM with a special focus on pancreatic, adipose tissue and vascular inflammation. In addition, we explore the role of soluble CD40L (sCD40L) as a potential biomarker for the development of cardiovascular disease in T2DM subjects. Finally, the therapeutic potential of CD40-CD40L inhibition in T2DM is highlighted.

show abstract

Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus

Cited by 47 publications

References 42 publications

Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients

Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients

New Aspects of Cellular Cholesterol Regulation on Blood Glucose Control—Review and Perspective on the Impact of Statin Medications on Metabolic Health

CD40–CD40L: Linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications

Contact Info

Product

Resources

About